Abstract:Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Ministry of Science, Innovation and Universities, Spain by Consejería de Educación, Cultura y Deportes. Junta de Comunidades de Castilla-La Mancha. Background Phospholamban regulates SERCA2a pump activity by reducing its calcium affinity in the heart. Under β-adrenergic stimulation, protein kinase A (PKA) phosphorylates phospholamban attenuating its inhibitory effect on SERCA2a. The phospholamban mutation Arg 9 to Cys (R9C) was firstly identified in an American family with ventricular dilatation and premature death, and subsequently in a cohort of dilated cardiomyopathy patients in South Africa. Emerging evidence suggests that phospholamban R9C is a loss-of-function mutation with autosomal dominant inheritance. In vitro studies revealed that it enhances pentamer assembly by disulfide bridge formation, reducing the availability of phospholamban monomers to regulate SERCA2a. Purpose The present study aimed to investigate defects in Ca2+ handling and cardiac function of phospholamban R9C mutation in an in vivo zebrafish model. Methods We generated transgenic zebrafish lines overexpressing phospholamban wild-type (TgPLNwt) and phospholamban R9C (TgPLNR9C) in the heart of zebrafish. To measure calcium kinetics in 3 day-old larvae, TgPLNwt and TgPLNR9C fish were outcrossed with transgenic zebrafish lines expressing the fluorescent calcium biosensor mCyRFP1-GCaMP6f (TgRFP-GcaMP6f) and the bioluminescence calcium biosensor GFP-Aequorin (TgGA) in the heart. Results Overexpression of phospholamban wild-type and R9C did not alter the heart rate compared to sibling larvae, and no differences were observed in the upstroke and recovery time of the calcium transients. However, atrial and ventricular calcium transient amplitude were higher in TgPLNR9C larvae with respect to TgPLNwt larvae. Contractile force of the heart, assessed as the fractional shortening, increased in TgPLNR9C larvae compared to siblings and TgPLNwt. Furthermore, stroke volume and cardiac output were also higher in TgPLNR9C larvae. Bioluminescence experiments were performed to estimate the average calcium levels in the heart. We found that TgPLNR9C larvae showed higher calcium levels than sibling and TgPLNwt larvae. To evaluate the responsiveness to β-adrenergic stimulation, larvae were treated with the β-agonist isoproterenol. Calcium transient amplitude and contractile force increased in sibling and TgPLNwt larvae after treatment. However, this response was absent in TgPLNR9C larvae, suggesting that they were hyper-stimulated in basal conditions, displaying amplitude and contractile force similar to sibling and TgPLNwt larvae treated with isoproterenol. Conclusion TgPLNR9C larvae exhibited aberrant calcium handling in the heart with higher calcium levels and contractility, consistent with a lack of inhibition of SERCA2a. Consequently, TgPLNR9C larvae did not respond to β-adrenergic stimulation. These results were consistent with previous in vitro studies carried out in cardiomyocites infected with phospholamban R9C and highlighted the pathological defects of phospholamban R9C at early stages of the disease.

The Critical Role of Phospholamban in Cardiac Function

Phospholamban Knockout Breaks Arrhythmogenic Ca2+ Waves and Suppresses Catecholaminergic Polymorphic Ventricular Tachycardia in Mice

Phospholemman Modulates Na+/Ca2+exchange in Adult Rat Cardiac Myocytes

Raav-Asplb Transfer Attenuates Abnormal Sarcoplasmic Reticulum Ca2+-Atpase Activity and Cardiac Dysfunction in Rats with Myocardial Infarction

Construction of Phospholamban Antisense RNA Recombinant Adenoassociated Virus Vector and Its Effects in Rat Cardiomyocytes

Partial Restoration of Left Ventricular Systolic Function by asPLB Gene Transfer Using Ultrasound-Mediated Microbubble Destruction

Understanding the Molecular Mechanism of PLCε Regulation and G Protein‐Mediated Activation

Rescue of Cardiomyocyte Dysfunction by Phospholamban Ablation Does Not Prevent Ventricular Failure in Genetic Hypertrophy.

Threonine-17 phosphorylation of phospholamban: a key determinant of frequency-dependent increase of cardiac contractility.

The human phospholamban gene: structure and expression

Phospholemman Modulates The Gating Of Cardiac L-Type Calcium Channels

Characterization of the Human and Rat Phospholemman (PLM) cDNAs and Localization of the Human PLM Gene to Chromosome 19q13.1

Dual Site Phospholamban Phosphorylation and Its Physiological Relevance in the Heart.

Early consequences of the phospholamban mutation PLN‐R14del+/− in a transgenic mouse model

Phosphoproteomics of PLN R14del heart tissue reveals major myocyte degenerate phenotype, and is attenuated by PLN antisense treatment in vitro

Phenotyping calcium and contraction in a zebrafish model of phospholamban R9C mutation

Molecular noise filtering in the β-adrenergic signaling network by phospholamban pentamers

Phospholamban phosphorylation increases the passive calcium leak from cardiac sarcoplasmic reticulum

Ranolazine Rescues the Heart Failure Phenotype of PLN-deficient Human Pluripotent Stem Cell-Derived Cardiomyocytes

Structures of PKA–phospholamban complexes reveal a mechanism of familial dilated cardiomyopathy

The Unfolded Protein Response as a Compensatory Mechanism and Potential Therapeutic Target in PLN R14del Cardiomyopathy